Ardent Health, Inc. Reports Q4 and Full-Year 2025 Results: Robust Growth, Balance Sheet Strength, and 2026 Guidance

Brentwood, Tenn., March 4, 2026 — Ardent Health, Inc. (NYSE: ARDT), a major healthcare provider in mid-sized urban communities across the U.S., has released its financial and operating results for the fourth quarter and full year ended December 31, 2025. The report includes detailed guidance for 2026, key non-GAAP disclosures, and commentary from management, making it a crucial update for investors and shareholders.

Key Financial Highlights

• Total Revenue: Q4 2025 revenue was \$1.61 billion. Full-year 2025 revenue reached \$6.32 billion, representing a 6.0% year-over-year (Y/Y) growth.
• Adjusted EBITDA: Q4 2025 Adjusted EBITDA was \$134 million (down 26.6% Y/Y). Full-year 2025 Adjusted EBITDA was \$545 million, up 9.3% Y/Y and with a margin expansion of 20 basis points to 8.6%.
• Net Income: Q4 2025 net income attributable to Ardent Health was \$45 million (\$0.32/diluted share), versus \$114 million (\$0.81/diluted share) in Q4 2024. Full-year net income attributable to Ardent was \$135.8 million (\$0.96/diluted share), down from \$210.3 million (\$1.58/diluted share) in 2024.
• Operating Cash Flow: Q4 2025 operating cash flow was \$223 million, up 87% Y/Y. Full-year operating cash flow reached \$471 million, up nearly 50% Y/Y.
• Balance Sheet: Cash and equivalents as of December 31, 2025: \$710 million. Total debt: \$1.1 billion. Net leverage ratio improved to 0.8x, lease-adjusted net leverage ratio to 2.5x (from 2.9x in 2024).

Key Operating Metrics

• Admissions: Q4 2025 admissions grew 1.5% Y/Y; adjusted admissions grew 2.0% Y/Y.
• Surgeries: Total surgeries increased 0.1% Y/Y, with inpatient surgeries up 3.9% and outpatient surgeries down 1.3%.
• Emergency Room Visits: Down 1.7% Y/Y in Q4 2025.
• Net Patient Service Revenue per Adjusted Admission: \$17,757 in Q4 2025, down 2.4% Y/Y.

Management Commentary & IMPACT Program Momentum

President and CEO Marty Bonick highlighted several crucial achievements:

• Expense optimization and disciplined execution drove solid Q4 EBITDA results.
• The IMPACT program resulted in significant SWB expense improvements, especially in contract labor.
• Payor denial and professional fee dynamics stabilized in Q4 2025.
• Ardent expects the IMPACT program to deliver \$55 million of savings in 2026, up from prior expectations of \$40 million.
• Focus remains on revenue optimization, expense management, productivity, and quality — all while navigating industry headwinds and the expiration of enhanced Exchange subsidies.

2026 Financial Guidance

• Total Revenue: \$6,400–\$6,700 million
• Net Income Attributable to Ardent Health: \$129–\$183 million
• Adjusted EBITDA: \$485–\$535 million
• Diluted EPS: \$0.90–\$1.27
• Adjusted Admissions Growth: 1.5%–2.5%
• Capital Expenditures: \$225–\$265 million

Shareholders should note: The guidance is based on current plans and known headwinds, such as elevated professional fees, payor denials, Exchange disruption, and restoration of short-term compensation, offset by core earnings growth and IMPACT program savings.

Shareholder-Focused Developments & Potential Price Sensitivity

• Expense Management: The IMPACT program’s increased savings estimate could positively affect margins and share value.
• Industry Headwinds: The annualization of elevated professional fees, payor denials, and expiration of enhanced Exchange subsidies are expected to impact 2026 results.
• Balance Sheet Strength: Improving net leverage and substantial cash reserves reduce risk and may support future capital deployment or shareholder returns.
• Stock Repurchase: Ardent repurchased 0.35 million shares for \$3 million in Q4 2025, with \$47 million remaining under its repurchase authorization, signaling confidence and return of capital to shareholders.
• Strategic Positioning: Management expects a return to adjusted EBITDA growth in 2027, leveraging durable demand, operational efficiencies, and capital deployment.
• Risks: Investors should be aware of ongoing risks, including regulatory changes (e.g., One Big Beautiful Bill Act), reimbursement trends, cybersecurity threats, and competitive pressures.

Non-GAAP Measures & Supplemental Information

Ardent Health uses non-GAAP metrics such as Adjusted EBITDA and Adjusted EBITDAR, which exclude certain non-cash, unusual, or non-recurring items, providing a clearer picture of ongoing operations. However, these measures have material limitations and should not be considered as substitutes for GAAP metrics.

Conference Call & Investor Engagement

Ardent will host a conference call to discuss results on March 5, 2026, at 10:00 a.m. Eastern Time. Investors can access the webcast or teleconference via the Investor Relations section of the corporate website.

Conclusion — Why This Matters for Investors

Ardent Health’s report signals robust operational and financial performance in 2025, a strong balance sheet, and prudent 2026 guidance amid industry headwinds. The IMPACT program’s increased savings, improved leverage ratios, and active capital management (including share repurchases) are positive developments that could impact share value. However, risks from reimbursement, regulation, and competitive dynamics remain and should be monitored.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review all relevant company filings and disclosures, and consult with professional advisors before making investment decisions. The financial outlook and forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated.

View Ardent Health, Inc. Historical chart here